Cambridge Capital Group reports two exits in 2021-23

Cambridge Capital Group reports two exits in 2021-23 from their Cambridge portfolio. Biotech business, Arecor, which develops enhanced reformulations of therapies for diabetes, listed on AIM; and appointments scheduling software business, 10to8, was recently sold in a Private Equity deal. Both delivered strong returns to early angel investors including members of Cambridge Capital Group. A further Medtech portfolio business is in final due diligence with a potential acquirer.